title: Protective effect of a JNK inhibitor against retinal ganglion cell loss induced by acute moderate ocular hypertension.
abstract: OBJECTIVE
  To correlate retinal ganglion cell (RGC) loss and optic nerve (ON) damage with the duration of acute glaucoma attacks in a rat experimental model and to determine whether the c-Jun N-terminal kinase (JNK) inhibitor SP600125 protects against such attacks.
  
  
  METHODS
  To model an acute glaucoma attack, rat intraocular pressure (IOP) was elevated by a controllable compression method using pulleys and specific weights. Intraocular pressure was measured with a TonoLab® rebound tonometer. Time-dependent ocular hypertension-induced damage was evaluated by ON morphology, retina morphology (both retina layer thickness in cross-sections and RGC counts in Dextran tetramethylrhodamine crystals [DTMR] labeled flatmounts), and scotopic flash electroretinography (ERG). A c-Jun N-terminal kinase (JNK) inhibitor, SP600125 (0, 1.5, 5, or 15 mg/kg), was administered by intraperitoneal injection immediately before and after induction of ocular hypertension, then once daily for seven days. Retinal cross-sections were measured to determine the thickness of various retinal layers and the cell density in the ganglion cell layer (GCL). Retinal flatmounts immunolabeled with anti-rat Brn-3a primary antibody were used to quantify RGC numbers.
  
  
  RESULTS
  Elevated rat IOP induced by corneal limbus compression correlated with the different weights. Elevation to 45 mmHg for up to 7 h did not significantly affect the thicknesses of the outer nuclear layer, outer plexiform layer, or inner nuclear layer. Amplitudes of A- and B-waves were not affected. However, elevation to 45 mmHg for up to 7 h decreased the inner retinal thickness and caused ON damage. Most importantly, IOP elevation induced a time-dependent RGC loss. Cell density in the GCL decreased to 70%, 62%, and 49% of that of the control after 5 h, 6 h, and 7 h, respectively, of pressure increases. In retinal flatmount studies, labeled RGCs were reduced 56±4% (mean±SEM) versus the control (p<0.001) after 7 h of ocular hypertension. SP600125 dose-dependently protected against ocular hypertension-induced RGC loss. The difference in RGC density between the vehicle and SP600125-treated (15 mg/kg) groups was statistically significant (p<0.001).
  
  
  CONCLUSIONS
  The correlation of inner retinal morphological changes with the duration of the application of 45 mmHg IOP was demonstrated. Treatment with SP600125 significantly protected RGC survival against this insult. Inhibitors of JNK may be an interesting pharmacological class for treating glaucoma.
authors.affiliation: Department of Physiology, Shandong University School of Medicine, Shandong, PR China.
authors.forename: Hui
authors.initials: H
authors.lastname: Sun
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Iok-Hou
authors.initials: IH
authors.lastname: Pang
authors.forename: Jiaquan
authors.initials: J
authors.lastname: Shen
authors.forename: Xia
authors.initials: X
authors.lastname: Tang
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Chuanyong
authors.initials: C
authors.lastname: Liu
authors.forename: Bing
authors.initials: B
authors.lastname: Li
mesh_terms: D000818:Animals; D000873:Anthracenes / Q000008:administration & dosage* / Q000627:therapeutic use; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D004195:Disease Models, Animal; D004596:Electroretinography; D005901:Glaucoma / Q000503:physiopathology / Q000517:prevention & control; D007429:Intraocular Pressure / Q000187:drug effects; D048031:JNK Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D008297:Male; D009798:Ocular Hypertension; D009900:Optic Nerve / Q000166:cytology / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012160:Retina / Q000378:metabolism / Q000503:physiopathology; D012165:Retinal Ganglion Cells / Q000166:cytology / Q000187:drug effects*; D014065:Tonometry, Ocular
chemical_list: D000873:Anthracenes; D047428:Protein Kinase Inhibitors; C432165:pyrazolanthrone; D048031:JNK Mitogen-Activated Protein Kinases